Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

Open in Screener

CTSO

Cytosorbents Corp

Jan 30 • 04:00PM ET

0.9900

Dollar change -0.0100
Percentage change -1.00	%

Healthcare • Medical Devices • USA • NASD

Peers: MDT ABT BSX BAX RMD EW DXCM PEN TFX GMED

| Held by: VTI VXF MSSM

Index	-	P/E	-	EPS (ttm)	-0.36	Insider Own	19.65%	Shs Outstand	54.50M	Perf Week	-3.88%
Market Cap	54.28M	Forward P/E	-	EPS next Y	-0.23	Insider Trans	0.48%	Shs Float	44.06M	Perf Month	5.33%
Income	-18.67M	PEG	-	EPS next Q	-0.05	Inst Own	30.41%	Short Float	4.16%	Perf Quarter	-1.98%
Sales	37.74M	P/S	1.44	EPS this Y	56.25%	Inst Trans	-2.03%	Short Ratio	6.82	Perf Half Y	-16.46%
Book/sh	0.24	P/B	4.15	EPS next Y	16.07%	ROA	-39.15%	Short Interest	1.83M	Perf Year	-2.94%
Cash/sh	0.10	P/C	9.54	EPS next 5Y	-	ROE	-118.50%	52W Range	0.70 - 1.59	Perf YTD	8.79%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-2.64%	ROI	-47.42%	52W High	-37.74%	Beta	0.62
Dividend TTM	-	Quick Ratio	1.58	Sales past 5Y	13.69%	Gross Margin	62.71%	52W Low	41.43%	ATR (14)	0.07
Dividend Ex-Date	-	Current Ratio	1.97	EPS Y/Y TTM	33.06%	Oper. Margin	-57.21%	RSI (14)	49.90	Volatility	5.12% 8.36%
Employees	186	Debt/Eq	2.06	Sales Y/Y TTM	1.80%	Profit Margin	-49.47%	Recom	2.00	Target Price	5.50
Option/Short	Yes / Yes	LT Debt/Eq	2.03	EPS Q/Q	79.30%	Payout	-	Rel Volume	0.39	Prev Close	1.00
Sales Surprise	-9.39%	EPS Surprise	-45.45%	Sales Q/Q	6.58%	Earnings	Nov 07 AMC	Avg Volume	268.98K	Price	0.99
SMA20	-1.61%	SMA50	4.27%	SMA200	0.30%	Trades		Volume	104,792	Change	-1.00%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-07-23	Initiated	B. Riley Securities	Buy	$4
Oct-14-21	Resumed	B. Riley Securities	Buy	$10
Sep-17-20	Initiated	Jefferies	Buy	$15
Sep-01-20	Initiated	SVB Leerink	Outperform	$15
Aug-08-17	Reiterated	Maxim Group	Buy	$10 → $12
Oct-26-16	Initiated	Aegis Capital	Buy
May-24-16	Initiated	Maxim Group	Buy	$8
Oct-29-15	Upgrade	WBB Securities	Speculative Buy → Buy	$13 → $13
May-12-15	Reiterated	MLV & Co	Buy	$28 → $21
Apr-01-15	Reiterated	MLV & Co	Buy	$28 → $30
Mar-05-15	Initiated	MLV & Co	Buy	$30
Feb-25-15	Initiated	WBB Securities	Speculative Buy	$13
Jan-27-15	Reiterated	H.C. Wainwright	Buy	$1 → $12

Show Previous Ratings

Jan-14-25 09:35AM	Cytosorbents Boosts Liquidity with Successful Rights Offering (TipRanks)
Jan-13-25 07:00AM	CytoSorbents Strengthens Balance Sheet with Closing of Oversubscribed Rights Offering (GlobeNewswire) +11.98%
Jan-06-25 07:00AM	CytoSorbents Expands Global Footprint with Opening of New Regional Sales Subsidiary in Dubai (GlobeNewswire) +11.04%
Jan-04-25 08:15AM	CytoSorbents reported strong Q4 results, says D. Boral Capital (TipRanks)
Jan-03-25 07:00AM	CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2024 Product Revenue (GlobeNewswire)
07:00AM	Loading…
Dec-23-24 07:00AM	CytoSorbents Rights Offering Begins (GlobeNewswire) -8.37%
Dec-12-24 07:00AM	CytoSorbents to Host Investor Meetings in San Francisco During J.P. Morgan Healthcare Conference Week (GlobeNewswire)
Dec-09-24 07:00AM	CytoSorbents Announces Rights Offering (GlobeNewswire)
Nov-26-24 07:00AM	CytoSorbents to Participate at the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire)
Nov-11-24 07:30AM	CytoSorbents And Converge Biotech Announce Strategic Partnership to Expand Sepsis and Critical Care Treatment with CytoSorb in India (GlobeNewswire) +25.68%
Nov-08-24 04:03PM	CytoSorbents Corp (CTSO) Q3 2024 Earnings Call Highlights: Strong Sales Growth and Improved ... (GuruFocus.com) -18.05%
Nov-07-24 05:58PM	CytoSorbents: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	CytoSorbents Reports Third Quarter 2024 Financial and Operational Results (GlobeNewswire)
Nov-06-24 07:54AM	CytoSorbents Corp (CTSO) Q3 2024: Everything You Need to Know Ahead of Earnings (GuruFocus.com) +6.61%
Nov-04-24 07:00AM	CytoSorbents Submits Health Canada Medical Device License Application for DrugSorb-ATR Following MDSAP Certification (GlobeNewswire) -12.95%
07:00AM	Loading…
Oct-22-24 07:00AM	FDA Accepts DrugSorb-ATR De Novo Application To Reduce the Severity of CABG-Related Bleeding Due to Ticagrelor and Initiates Substantive Review (GlobeNewswire)
Oct-17-24 07:00AM	CytoSorbents to Report Third Quarter 2024 Operating and Financial Results (GlobeNewswire)
Oct-09-24 06:19PM	CytoSorbents Corp (CTSO) Q2 2024 Earnings Call Highlights: Revenue Growth and Strategic ... (GuruFocus.com) -7.08%
Oct-01-24 07:00AM	CytoSorbents Submits DrugSorb-ATR Marketing Application to U.S. FDA to Reduce the Severity of Bleeding in Heart Bypass Surgery Patients on the Blood Thinner Ticagrelor and Provides Business Update (GlobeNewswire) -10.00%
Aug-27-24 07:00AM	CytoSorbents to Present at the H.C. Wainwright 26?? Annual Global Investment Conference (GlobeNewswire)
Aug-16-24 04:05PM	CytoSorbents Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-13-24 05:45PM	CytoSorbents: Q2 Earnings Snapshot (Associated Press Finance) +7.99%
04:19PM	CytoSorbents Reports Second Quarter 2024 Financial and Operational Results (GlobeNewswire)
04:18PM	CytoSorbents Appoints Peter J. Mariani Chief Financial Officer (GlobeNewswire)
Aug-07-24 07:00AM	CytoSorbents to Report Second Quarter 2024 Operating and Financial Results (GlobeNewswire) +7.92%
Aug-01-24 07:00AM	CytoSorbents Announces Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
Jul-30-24 02:00AM	CytoSorbents Unveils Newly Redesigned, Unified Company and Product Website (GlobeNewswire)
Jul-29-24 08:00AM	CytoSorbents Unveils Newly Redesigned, Unified Company and Product Website (GlobeNewswire) +17.48%
Jul-17-24 07:00AM	CytoSorbents to Present at the Inaugural American Association of Physicians of Indian Origin (AAPI) World Health Congress (GlobeNewswire)
Jul-02-24 07:00AM	CytoSorbents Secures $20 Million Credit Facility (GlobeNewswire) +17.40%
07:00AM	Loading…
Jun-24-24 07:00AM	CytoSorbents Announces Regulatory Approval of CytoSorb in Taiwan (GlobeNewswire)
Jun-13-24 07:00AM	CytoSorbents Announces the Launch and Immediate Availability of the PuriFi Blood Pump in the European Union (GlobeNewswire)
Jun-05-24 07:00AM	CytoSorbents to Host its 2024 Virtual Annual Stockholders Meeting (GlobeNewswire) +5.04%
Jun-04-24 07:00AM	CytoSorbents STAR Registry Data on Patients on Ticagrelor Undergoing CABG Surgery with CytoSorb Presented at EuroPCR 2024. Named Top Five Finalist for Best Scientific Abstract (GlobeNewswire)
May-10-24 12:10PM	Cytosorbents Corporation (NASDAQ:CTSO) Q1 2024 Earnings Call Transcript (Insider Monkey) +12.30%
May-09-24 04:24PM	CytoSorbents: Q1 Earnings Snapshot (Associated Press Finance) -7.10%
04:17PM	CytoSorbents Reports First Quarter 2024 Results (GlobeNewswire)
May-02-24 07:00AM	CytoSorbents May 6, 2024 Virtual KOL and Analyst-Investor Day: STAR-T Pivotal Trial Topline Results & Real World Experience with Antithrombotic Drug Removal in Europe (GlobeNewswire)
Apr-26-24 07:00AM	CytoSorbents to Report First Quarter 2024 Operating and Financial Results (GlobeNewswire)
Apr-17-24 07:00AM	STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting (GlobeNewswire)
Mar-15-24 10:14AM	Cytosorbents Corporation (NASDAQ:CTSO) Q4 2023 Earnings Call Transcript (Insider Monkey) -9.27%
06:28AM	Q4 2023 Cytosorbents Corp Earnings Call (Thomson Reuters StreetEvents)
Mar-14-24 09:53PM	CTSO Stock Earnings: CytoSorbents Beats EPS, Misses Revenue for Q4 2023 (InvestorPlace)
04:39PM	CytoSorbents Reports Fourth Quarter and Full Year 2023 Results (GlobeNewswire)
Mar-06-24 07:00AM	CytoSorbents to Report Fiscal 2023 Operating and Financial Results (GlobeNewswire)
Feb-08-24 07:00AM	CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
Jan-17-24 07:15AM	Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb Intraoperatively in Heart Transplant Patients (GlobeNewswire)
Dec-28-23 07:00AM	CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation (GlobeNewswire) -33.44%
Dec-16-23 07:01AM	Insider Buying: CEO Phillip Chan Acquires 75,188 Shares of CytoSorbents Corp (CTSO) (GuruFocus.com)
Dec-13-23 09:15AM	CytoSorbents Announces Closing of $10.3 Million Registered Direct Offering (GlobeNewswire) +21.53%
Nov-10-23 09:42AM	Q3 2023 Cytosorbents Corp Earnings Call (Thomson Reuters StreetEvents)
08:52AM	Cytosorbents Corporation (NASDAQ:CTSO) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-09-23 05:47PM	CytoSorbents: Q3 Earnings Snapshot (Associated Press Finance) -11.27%
04:15PM	CytoSorbents Reports Third Quarter 2023 Financial and Operational Results (GlobeNewswire)
Oct-27-23 07:00AM	CytoSorbents to Report Third Quarter 2023 Operating and Financial Results (GlobeNewswire) -7.83%
Oct-05-23 07:00AM	CytoSorbents to Present at the 8th Annual Dawson James Conference (GlobeNewswire)
Sep-27-23 07:00AM	CytoSorbents Highlights Upcoming Presentations at EACTS 2023: Focus on Antithrombotic Removal including the 2nd Analysis of the International STAR Registry (GlobeNewswire)
Sep-21-23 09:35AM	Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference (GlobeNewswire)
Sep-19-23 07:00AM	CytoSorbents Announces Kathleen P. Bloch To Resume as Full-Time Chief Financial Officer (GlobeNewswire)
Sep-11-23 11:32AM	CytoSorb with Ex Vivo Organ Perfusion: Transforming the Future of Solid Organ Transplantation (GlobeNewswire)
Sep-01-23 04:43PM	CytoSorbents Announces Resignation of Chief Financial Officer Alexander DAmico (GlobeNewswire)
Aug-31-23 07:00AM	CytoSorbents Granted Expanded ANVISA Registration to Treat Shock with CytoSorb in Brazil (GlobeNewswire)
Aug-14-23 07:00AM	CytoSorbents Completes U.S. and Canadian STAR-T Pivotal Trial (PR Newswire)
Aug-03-23 09:10AM	CTSO: CytoSorbents reports 2nd quarter 2023 financial and results which showed strong product revenue growth and an improved cost structure. (Zacks Small Cap Research) -5.07%
Aug-02-23 09:02AM	Q2 2023 Cytosorbents Corp Earnings Call (Thomson Reuters StreetEvents) -7.46%
Aug-01-23 04:23PM	CytoSorbents: Q2 Earnings Snapshot (AP Finance)
04:15PM	CytoSorbents Reports Second Quarter 2023 Financial and Operational Results (GlobeNewswire)
Jul-31-23 07:31AM	Several Insiders Invested In Cytosorbents Flagging Positive News (Simply Wall St.)
Jul-26-23 07:00AM	CytoSorbents to Report Second Quarter 2023 Operating and Financial Results (GlobeNewswire)
Jul-19-23 07:00AM	CytoSorbents Appoints Alexander DAmico as Chief Financial Officer (GlobeNewswire)
Jul-11-23 07:00AM	CytoSorbents And Humedics Announce Theranostic Collaboration in the Field of Liver Disease (GlobeNewswire) +11.49%
Jul-09-23 09:00AM	Cytosorbents Corporation's (NASDAQ:CTSO) largest shareholders are retail investors with 52% ownership, institutions own 33% (Simply Wall St.)
Jul-07-23 07:07AM	CytoSorbents Completes Enrollment of the STAR-T Pivotal Trial (GlobeNewswire)
Jun-15-23 07:00AM	CytoSorbents Announces Independent Data Safety and Monitoring Board Recommends Completion of the Pivotal STAR-T Trial Without Modifications Following Second Scheduled Safety Review (GlobeNewswire)
Jun-05-23 09:00AM	CytoSorbents This Week to Host its Virtual Annual Stockholders Meeting and to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-05-23 07:18AM	Cytosorbents Corporation (NASDAQ:CTSO): Is Breakeven Near? (Simply Wall St.)
May-04-23 10:31AM	CTSO: CytoSorbents reports 1st quarter 2023 financial and operating results which showed sequential revenue growth on a Core Product constant currency basis. (Zacks Small Cap Research)
May-03-23 07:42AM	Q1 2023 Cytosorbents Corp Earnings Call (Thomson Reuters StreetEvents) +16.46%
May-02-23 04:23PM	CytoSorbents: Q1 Earnings Snapshot (AP Finance)
04:15PM	CytoSorbents Reports First Quarter 2023 Results (GlobeNewswire)
Apr-26-23 07:00AM	CytoSorbents to Report First Quarter 2023 Operating and Financial Results (GlobeNewswire) -8.89%
Apr-20-23 07:00AM	CytoSorbents Pivotal STAR-T Trial Reaches Second Key Milestone With 80 Patients Enrolled (GlobeNewswire)
Apr-19-23 07:00AM	CytoSorbents Announces Board Chairman Al W. Kraus To Retire (GlobeNewswire)
Apr-17-23 10:47AM	Cytosorbents Corporation (NASDAQ:CTSO) Might Not Be As Mispriced As It Looks (Simply Wall St.)
Mar-29-23 08:30AM	Landmark Publication Underscores Robust Ability of CytoSorb to Reduce Cytokine Storm during Systemic Hyperinflammation (GlobeNewswire)
Mar-22-23 08:09AM	CytoSorbents Highlights New Clinical Data from Current Studies at the Live 42nd International Symposium on Intensive Care & Emergency Medicine (ISICEM) (GlobeNewswire)
Mar-20-23 07:38AM	Investors in Cytosorbents (NASDAQ:CTSO) have unfortunately lost 57% over the last five years (Simply Wall St.)
Mar-17-23 09:10AM	CTSO: UPDATE: CytoSorbents reports 4th quarter and fiscal 2022 financial and operating results which showed positive revenue growth on a Core Product constant currency basis. (Zacks Small Cap Research)
Mar-14-23 07:00AM	CytoSorbents Comments on Bank Exposure and Diversified Cash Position (GlobeNewswire)
Mar-13-23 02:53AM	Cytosorbents Corporation (NASDAQ:CTSO) Q4 2022 Earnings Call Transcript (Insider Monkey) -8.52%
Mar-10-23 10:33AM	Q4 2022 Cytosorbents Corp Earnings Call (Thomson Reuters StreetEvents)
Mar-09-23 04:15PM	CytoSorbents Reports Fourth Quarter and Full Year 2022 Results (GlobeNewswire)
Mar-07-23 07:00AM	New European Guidelines for the Management of Severe Perioperative Bleeding Consider Hemoadsorption for the First-Time (GlobeNewswire) +20.25%
Feb-27-23 07:00AM	CytoSorbents to Present at the Cowen 43rd Annual Health Care Conference (PR Newswire)
Feb-24-23 07:00AM	CytoSorbents to Report Fiscal 2022 Operating and Financial Results (PR Newswire)
Feb-21-23 06:22AM	Quite a few insiders invested in Cytosorbents Corporation (NASDAQ:CTSO) last year which is positive news for shareholders (Simply Wall St.)
Feb-15-23 08:20AM	CTSO: INITIATION: Established medical device company with advanced proprietary blood purification technologies positioned for rapid profitable growth going forward. (Zacks Small Cap Research)
Jan-31-23 07:15AM	CytoSorbents Issues Stockholder Letter and Reports Preliminary Fourth Quarter and Full Year 2022 Revenue (PR Newswire) +25.44%
Jan-29-23 09:58AM	Cytosorbents Corporation's (NASDAQ:CTSO) market cap touched US$103m last week, benefiting both individual investors who own 52% as well as institutions (Simply Wall St.)
Jan-23-23 07:00AM	CytoSorbents Announces Health Canada Regulatory Approval For Pivotal STAR-T Trial (PR Newswire)

CytoSorbents Corp. engages in critical care immunotherapy, investigation, and commercialization of blood purification technology. Its product portfolio includes CytoSorb, ContrastSorb XL, HemoDefend, VetResQ, and DrugSorb. The company was founded by Joseph Rubin in August 1997 and is headquartered in Princeton, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MARIANI PETER J	Chief Financial Officer	Dec 13 '24	Buy	0.96	20,000	19,294	401,363	Dec 16 07:00 AM
MARIANI PETER J	Chief Financial Officer	Dec 12 '24	Buy	0.89	20,000	17,872	381,363	Dec 13 08:00 AM
MARIANI PETER J	Chief Financial Officer	Dec 11 '24	Buy	0.89	11,363	10,103	361,363	Dec 13 08:00 AM

Open in Screener

AXGN

Axogen Inc

Jan 30 • 04:00PM ET

18.27

Dollar change -0.04
Percentage change -0.22	%

Healthcare • Medical Devices • USA • NASD

Peers: IART BAX SYK ZBH MDT JNJ GMED EW PODD HOLX

| Held by: VTI IWM VXF IWO FESM IHI SCHA VTWO DFAS IWC

Index	RUT	P/E	-	EPS (ttm)	-0.33	Insider Own	5.60%	Shs Outstand	44.00M	Perf Week	-2.30%
Market Cap	804.03M	Forward P/E	57.70	EPS next Y	0.32	Insider Trans	0.00%	Shs Float	41.54M	Perf Month	9.66%
Income	-14.31M	PEG	-	EPS next Q	0.03	Inst Own	83.42%	Short Float	2.99%	Perf Quarter	31.06%
Sales	180.86M	P/S	4.45	EPS this Y	145.36%	Inst Trans	0.68%	Short Ratio	2.87	Perf Half Y	108.09%
Book/sh	2.26	P/B	8.09	EPS next Y	310.61%	ROA	-7.40%	Short Interest	1.24M	Perf Year	88.74%
Cash/sh	0.69	P/C	26.34	EPS next 5Y	-	ROE	-14.51%	52W Range	5.55 - 19.06	Perf YTD	10.86%
Dividend Est.	-	P/FCF	-	EPS past 5Y	3.44%	ROI	-8.60%	52W High	-4.14%	Beta	0.99
Dividend TTM	-	Quick Ratio	2.47	Sales past 5Y	10.55%	Gross Margin	76.40%	52W Low	229.19%	ATR (14)	0.89
Dividend Ex-Date	Jan 27, 2010	Current Ratio	3.74	EPS Y/Y TTM	39.37%	Oper. Margin	-4.70%	RSI (14)	59.51	Volatility	4.08% 6.35%
Employees	428	Debt/Eq	0.69	Sales Y/Y TTM	18.79%	Profit Margin	-7.91%	Recom	1.14	Target Price	19.71
Option/Short	Yes / Yes	LT Debt/Eq	0.67	EPS Q/Q	55.47%	Payout	-	Rel Volume	0.51	Prev Close	18.31
Sales Surprise	3.35%	EPS Surprise	1066.67%	Sales Q/Q	17.86%	Earnings	Nov 07 BMO	Avg Volume	434.10K	Price	18.27
SMA20	4.12%	SMA50	16.04%	SMA200	58.75%	Trades		Volume	219,426	Change	-0.22%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-01-24	Initiated	Raymond James	Outperform	$13
Nov-11-22	Resumed	Jefferies	Buy	$15
May-09-22	Upgrade	Canaccord Genuity	Hold → Buy	$10 → $15
Mar-11-22	Resumed	Cantor Fitzgerald	Overweight	$21
Oct-23-20	Initiated	Guggenheim	Buy	$24
Jun-16-20	Resumed	Cantor Fitzgerald	Overweight	$16
May-07-20	Downgrade	Canaccord Genuity	Buy → Hold	$12
Apr-02-20	Downgrade	BTIG Research	Buy → Neutral
Aug-07-19	Downgrade	William Blair	Outperform → Mkt Perform
Jul-12-19	Initiated	Canaccord Genuity	Buy	$32
Mar-02-18	Reiterated	Lake Street	Buy	$26 → $38
Jan-05-18	Resumed	Cantor Fitzgerald	Overweight
Nov-30-17	Initiated	Jefferies	Buy	$35
Nov-21-17	Reiterated	Lake Street	Buy	$22 → $26
Jul-31-17	Initiated	Leerink Partners	Outperform	$22
Jun-30-17	Initiated	Cantor Fitzgerald	Overweight	$18
Mar-06-17	Initiated	ROTH Capital	Buy	$14.50
Nov-22-16	Upgrade	Lake Street	Hold → Buy	$9 → $11
Nov-07-16	Reiterated	Wedbush	Outperform	$10 → $12
Nov-03-16	Downgrade	Lake Street	Buy → Hold	$9

Show Previous Ratings

Jan-13-25 09:35AM	AxoGen, Inc. (AXGN) Soars to 52-Week High, Time to Cash Out? (Zacks)
05:05AM	AxoGen (AXGN) Moves 18.2% Higher: Will This Strength Last? (Zacks)
Jan-10-25 05:00PM	Axogen Announces New VP of Operations and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +18.21%
08:00AM	Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2024 (GlobeNewswire)
Dec-24-24 09:15AM	AxoGen, Inc. (AXGN) Hits Fresh High: Is There Still Room to Run? (Zacks) -5.41%
09:40AM	Loading…
Dec-19-24 09:40AM	Is AxoGen (AXGN) Stock Outpacing Its Medical Peers This Year? (Zacks)
Nov-28-24 12:00PM	All You Need to Know About AxoGen (AXGN) Rating Upgrade to Buy (Zacks)
Nov-25-24 09:55AM	How Much Upside is Left in AxoGen (AXGN)? Wall Street Analysts Think 31.18% (Zacks)
Nov-08-24 07:35AM	AxoGen Reports Strong Q3 2024 Revenue Growth (TipRanks)
02:08AM	Axogen Inc (AXGN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Advancements (GuruFocus.com)
Nov-07-24 07:48AM	AxoGen: Q3 Earnings Snapshot (Associated Press Finance) -13.44%
07:00AM	Axogen, Inc Reports Third Quarter 2024 Financial Results and Provides BLA Update (GlobeNewswire)
Oct-24-24 07:00AM	Axogen, Inc. to report third quarter 2024 financial results and host conference call on November 7, 2024 (GlobeNewswire)
Oct-14-24 07:21AM	AxoGen (AXGN) Surges 8.2%: Is This an Indication of Further Gains? (Zacks)
Oct-09-24 05:30PM	Axogen Inc (AXGN) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Raised Guidance ... (GuruFocus.com)
01:30AM	Loading…
Sep-12-24 01:30AM	ArrowMark Colorado Holdings LLC Reduces Stake in Axogen Inc (GuruFocus.com)
Sep-06-24 07:00AM	Axogen Completes Submission of Biologics License Application to U.S. Food and Drug Administration for Avance Nerve Graft (GlobeNewswire)
Sep-04-24 09:15AM	AxoGen, Inc. (AXGN) Hit a 52 Week High, Can the Run Continue? (Zacks)
Sep-03-24 07:00AM	Axogen Reports Inducement Grant to New Employee Under NASDAQ Listing Rule 5635(C)(4) (GlobeNewswire)
Aug-30-24 12:00PM	What Makes AxoGen (AXGN) a Strong Momentum Stock: Buy Now? (Zacks)
Aug-23-24 09:55AM	Wall Street Analysts See a 25.51% Upside in AxoGen (AXGN): Can the Stock Really Move This High? (Zacks)
Aug-19-24 09:15AM	AxoGen, Inc. (AXGN) Hits Fresh High: Is There Still Room to Run? (Zacks)
Aug-13-24 04:18PM	CytoSorbents Appoints Peter J. Mariani Chief Financial Officer (GlobeNewswire)
Aug-09-24 12:56AM	Axogen names ex-Abbott exec Michael Dale as CEO (MedTech Dive)
Aug-08-24 08:20AM	AxoGen (AXGN) Q2 Earnings and Revenues Beat Estimates (Zacks) +35.10%
07:19AM	AxoGen: Q2 Earnings Snapshot (Associated Press Finance)
07:05AM	Axogen, Inc. Announces New Leadership Appointments (GlobeNewswire)
07:00AM	Axogen, Inc. Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Aug-01-24 10:01AM	AxoGen (AXGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks) -7.06%
Jul-23-24 07:00AM	Axogen, Inc. to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024 (GlobeNewswire)
08:37AM	Loading…
Jul-12-24 08:37AM	AxoGen (AXGN) Soars 8.2%: Is Further Upside Left in the Stock? (Zacks)
Jul-01-24 07:00AM	Company Reports Inducement Grants to Non-Executive New Employee Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire) +6.49%
Jun-25-24 12:52PM	AxoGen's (AXGN) New Launch to Aid Peripheral Nerve Protection (Zacks)
Jun-24-24 07:00AM	Axogen, Inc Announces Full Launch of Avive+ Soft Tissue Matrix (GlobeNewswire)
Jun-12-24 04:56AM	Strength Seen in AxoGen (AXGN): Can Its 5.4% Jump Turn into More Strength? (Zacks) +9.21%
May-28-24 04:30PM	Axogen Processing Center (APC) Celebrates its Opening with Ohio Leaders in Vandalia (GlobeNewswire) +5.90%
May-17-24 12:29PM	AxoGen (AXGN) Initiates BLA Submission for Avance Nerve Graft (Zacks)
May-16-24 02:56PM	AxoGen Initiates Rolling Submission to FDA For Avance Nerve Graft (MT Newswires)
07:00AM	Axogen Inc. Initiates Rolling Submission of Biologics License Application to U.S. Food and Drug Administration (FDA) for Avance Nerve Graft (GlobeNewswire)
May-14-24 07:00AM	Axogen, Inc to Participate at Leerink Partners Healthcare Crossroads Conference (GlobeNewswire)
May-06-24 10:31AM	AxoGen, Inc. (NASDAQ:AXGN) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-03-24 03:02AM	Axogen Inc (AXGN) Q1 2024 Earnings Call Transcript Highlights: Navigating Growth Amidst Challenges (GuruFocus.com)
May-02-24 11:57AM	AXGN Stock Earnings: Axogen Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace) -10.37%
08:15AM	AxoGen (AXGN) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:14AM	AxoGen: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Axogen, Inc Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-29-24 04:50PM	Axogen Announces First Surgical Implants of Avive+ Soft Tissue Matrix (GlobeNewswire)
Apr-16-24 07:00AM	Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024 (GlobeNewswire)
Mar-08-24 11:55PM	Director Gregory Freitag Sells 25,000 Shares of Axogen Inc (AXGN) (GuruFocus.com)
Mar-06-24 08:20AM	AxoGen, Inc. (NASDAQ:AXGN) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-05-24 09:27PM	Q4 2023 AxoGen Inc Earnings Call (Thomson Reuters StreetEvents) -15.11%
11:53AM	AXGN Stock Earnings: Axogen Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace)
07:38AM	AxoGen: Q4 Earnings Snapshot (Associated Press Finance)
07:31AM	Axogen Inc (AXGN) Reports Growth in Revenue and Reduction in Net Loss for Q4 and Full-Year 2023 (GuruFocus.com)
07:00AM	Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results (GlobeNewswire)
Feb-28-24 08:50AM	AxoGen (AXGN) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Feb-26-24 09:15AM	AxoGen, Inc. (AXGN) Hit a 52 Week High, Can the Run Continue? (Zacks)
Feb-13-24 04:30PM	Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024 (GlobeNewswire)
Feb-12-24 08:50AM	Here's Why Momentum in AxoGen (AXGN) Should Keep going (Zacks)
Feb-06-24 09:40AM	Is AxoGen (AXGN) Stock Outpacing Its Medical Peers This Year? (Zacks)
Feb-02-24 04:15PM	Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Jan-26-24 08:50AM	Here's What Could Help AxoGen (AXGN) Maintain Its Recent Price Strength (Zacks)
Jan-18-24 05:00PM	Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap (GlobeNewswire) +7.86%
Jan-04-24 04:45PM	Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2023 (GlobeNewswire) +26.67%
04:40PM	Axogen Announces Plan for Leadership Transition with CEO Karen Zaderej to Retire from Company by January 2025 (GlobeNewswire)
04:35PM	Axogen Announces Promotions on Research and Development Team (GlobeNewswire)
Dec-26-23 04:15PM	Axogen, Inc. Appoints Kathy Weiler to its Board of Directors (GlobeNewswire)
Dec-06-23 07:00AM	Axogen Announces Transition of Finance Team Leadership (GlobeNewswire) +5.19%
Dec-01-23 05:00PM	Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.04%
Nov-20-23 07:00AM	Axogen, Inc. to Participate at the Piper Sandler 35th Annual Healthcare Conference (GlobeNewswire)
Nov-08-23 09:41AM	AxoGen, Inc. (NASDAQ:AXGN) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-07-23 11:01PM	Q3 2023 AxoGen Inc Earnings Call (Thomson Reuters StreetEvents) +36.90%
08:04AM	Axogen Inc (AXGN) Reports 12% Revenue Growth in Q3 2023 (GuruFocus.com)
07:15AM	AxoGen: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Axogen, Inc. Reports 2023 Third Quarter Financial Results (GlobeNewswire)
Nov-02-23 10:00AM	Dynatronics Corporation (DYNT) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release (Zacks) +5.26%
Oct-31-23 10:01AM	AxoGen (AXGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Oct-18-23 07:00AM	Axogen, Inc. to Report Third Quarter 2023 Financial Results and Host Conference Call on November 7, 2023 (GlobeNewswire)
Oct-16-23 10:23AM	Wayfair upgraded, JD.com downgraded: Wall Street's top analyst calls (The Fly) +5.28%
Sep-28-23 08:21AM	AxoGen (AXGN) Moves 6.8% Higher: Will This Strength Last? (Zacks)
Sep-05-23 07:00AM	Axogen, Inc. Announces Full Launch of Axoguard HA+ Nerve Protector (GlobeNewswire)
Aug-31-23 07:00AM	Axogen to Participate at Upcoming Investor Conferences (GlobeNewswire)
Aug-21-23 07:00AM	Axogen, Inc. Begins Processing Avance® Nerve Graft at New State-of-the-Art Facility in Dayton, Ohio (GlobeNewswire)
Aug-10-23 03:03PM	ArrowMark Colorado Holdings LLC Boosts Stake in Axogen Inc (GuruFocus.com) -6.51%
12:05PM	AxoGen, Inc. (NASDAQ:AXGN) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-08-23 10:59AM	The past five years for AxoGen (NASDAQ:AXGN) investors has not been profitable (Simply Wall St.) -19.44%
05:57AM	Q2 2023 AxoGen Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-07-23 05:25PM	AxoGen (AXGN) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:18PM	AxoGen: Q2 Earnings Snapshot (AP Finance)
04:01PM	Axogen, Inc. Reports 2023 Second Quarter Financial Results (GlobeNewswire)
Aug-03-23 05:55PM	Artivion (AORT) Q2 Earnings and Revenues Top Estimates (Zacks)
Jul-27-23 07:00AM	Axogen to Participate at Canaccord Genuitys 43rd Annual Growth Conference (GlobeNewswire) -6.83%
Jul-26-23 07:00AM	Axogen, Inc. to report second quarter 2023 financial results and host conference call on August 7, 2023 (GlobeNewswire)
Jun-10-23 10:42AM	With 71% ownership, AxoGen, Inc. (NASDAQ:AXGN) boasts of strong institutional backing (Simply Wall St.)
Jun-09-23 09:55AM	Wall Street Analysts Think AxoGen (AXGN) Could Surge 69.62%: Read This Before Placing a Bet (Zacks)
May-24-23 07:00AM	Axogen to Participate at Jefferies Healthcare Conference (GlobeNewswire)
May-12-23 07:00AM	Axogen to Participate at JMP Securities Life Sciences Conference (GlobeNewswire)
May-09-23 08:35AM	AxoGen (AXGN) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:34AM	AxoGen: Q1 Earnings Snapshot (AP Finance)
07:00AM	Axogen, Inc. Reports 2023 First Quarter Financial Results (GlobeNewswire)

Axogen, Inc. engages in the development and market of surgical solutions for peripheral nerve regeneration and repair. It also provides products and education to improve surgical treatment algorithms for peripheral nerve damage or discontinuity. The firm's products include avance nerve graft, axoguard nerve connector, axoguard nerve protector, avive soft tissue membrane, acroval neurosensory and motor testing system, and axotouch two-point discriminator. The company was founded in 1977 and is headquartered in Alachua, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Zaderej Karen L.	SENIOR ADVISOR	Jan 21 '25	Proposed Sale	18.41	220,000	4,050,000		Jan 21 01:20 PM
Zaderej Karen L.	SENIOR ADVISOR	Jan 14 '25	Proposed Sale	18.00	100,000	1,800,000		Jan 14 01:24 PM
Zaderej Karen L.	SENIOR ADVISOR	Nov 07 '24	Proposed Sale	12.71	70,000	890,000		Nov 07 10:52 AM
Zaderej Karen L.	SENIOR ADVISOR	Sep 05 '24	Proposed Sale	13.00	150,000	1,950,000		Sep 05 04:33 PM
JOHNSON JOHN	Director	Sep 01 '24	Option Exercise	0.00	11,904	0	29,016	Sep 04 09:13 PM
NEELS GUIDO J	Director	Sep 01 '24	Option Exercise	0.00	11,904	0	90,816	Sep 04 09:11 PM
Levine Alan M	Director	Sep 01 '24	Option Exercise	0.00	11,904	0	40,816	Sep 04 08:58 PM
Burke William P. Mr.	Director	Sep 01 '24	Option Exercise	0.00	11,904	0	28,557	Sep 04 08:52 PM
THOMAS PAUL	Director	Sep 01 '24	Option Exercise	0.00	11,904	0	32,052	Sep 04 08:33 PM
TYNDALL JOSEPH A.	Director	Sep 01 '24	Option Exercise	0.00	11,904	0	22,557	Sep 04 07:52 PM
Wendell Amy McBride	Director	Sep 01 '24	Option Exercise	0.00	11,904	0	102,899	Sep 04 05:18 PM
Donovan Michael Patrick	Officer	Aug 21 '24	Proposed Sale	12.42	28,003	347,810		Aug 21 04:31 PM
GREG FREITAG	Director	Aug 13 '24	Proposed Sale	11.17	15,000	167,520		Aug 13 05:00 PM
Zaderej Karen L.	SENIOR ADVISOR	Aug 12 '24	Proposed Sale	10.00	200,000	2,000,000		Aug 12 10:59 AM
Freitag Gregory Gene	Director	Jun 04 '24	Option Exercise	0.00	11,904	0	283,498	Jun 06 04:49 PM
Zaderej Karen L.	CEO	Mar 16 '24	Option Exercise	0.00	110,322	0	1,157,593	Mar 25 09:43 PM
Zaderej Karen L.	CEO	Mar 21 '24	Sale	7.68	39,280	301,670	1,124,565	Mar 25 09:43 PM
DeVinney Erick Wayne	Chief Innovation Officer	Mar 16 '24	Option Exercise	0.00	18,675	0	180,615	Mar 25 09:40 PM
DeVinney Erick Wayne	Chief Innovation Officer	Mar 21 '24	Sale	7.68	4,578	35,159	165,661	Mar 25 09:40 PM
Scopelianos Angelo	Chief R&D Officer	Mar 21 '24	Option Exercise	0.00	2,500	0	58,604	Mar 25 09:37 PM
Scopelianos Angelo	Chief R&D Officer	Mar 16 '24	Option Exercise	0.00	25,406	0	58,250	Mar 25 09:37 PM
Scopelianos Angelo	Chief R&D Officer	Mar 21 '24	Sale	7.68	6,881	52,846	52,999	Mar 25 09:37 PM
Donovan Michael Patrick	VP Operations	Mar 16 '24	Option Exercise	0.00	24,575	0	58,846	Mar 25 09:22 PM
Donovan Michael Patrick	VP Operations	Mar 21 '24	Sale	7.68	6,033	46,333	37,992	Mar 25 09:22 PM
Donovan Michael Patrick	VP Operations	Mar 07 '24	Sale	8.81	36,310	319,891	35,708	Mar 08 05:33 PM
Freitag Gregory Gene	Director	Mar 07 '24	Sale	9.00	25,000	225,000	271,594	Mar 08 05:31 PM

CTSO

Cytosorbents Corp

AXGN

Axogen Inc

Upgrade your FINVIZ experience